Coverage of Health Care Sector Stocks -- Research on Agilent Technologies, Thermo Fisher Scientific, Nordion, and BG Medicine
PR Newswire - Tue Apr 15, 10:08AM CDT
On Monday, April 14, 2014, the NASDAQ Composite ended at 4,022.69, up 0.57%, the Dow Jones Industrial Average advanced 0.91% to 16,173.24, and the S&P 500 closed at 1,830.61, up 0.82%. The gains were broad based as all the 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 648.05, up 0.51%, while the same has declined 3.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), Nordion Inc. (NYSE: NDZ) and BG Medicine Inc. (NASDAQ: BGMD). Free technical research on A, TMO, NDZ and BGMD can be downloaded upon signing up at:
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR), BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Barnes & Noble Sinks after Liberty Media Sells Off Big Stake; Adobe Systems Insiders also Sell off Shares
ACCESSWIRE - Thu Apr 03, 11:21PM CDT
Barnes & Noble, Inc. (NYSE: BKS) - For an in-depth report on Barnes & Noble, Inc. follow: www.BullTrends.com/stockquote/BKS
Why BG Medicine (BGMD) Is Tumbling on Thursday
at The Street - Thu Apr 03, 11:25AM CDT
BG Medicine (BGMD) is plummeting on Thursday in response to its pricing of common stock in its latest public offering.
BG Medicine, Inc. Prices $10.0 Million Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 8:15AM CDT
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, today announced the pricing of the sale of 6,452,000 shares of its common stock in an underwritten public offering at a price to the public of $1.55 per share. The net offering proceeds to BG Medicine from the sale of the shares are expected to be approximately $8.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriter's over-allotment option.
BG Medicine, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Apr 02, 3:05PM CDT
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering. While the offering is expected to price before 9:30 am EDT on April 3, 2014, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Hewlett-Packard to Enter the 3d Printing Market; BG Medicine Announces Positive Data from Clinical Research Trials
ACCESSWIRE - Tue Mar 25, 11:25PM CDT
Hewlett-Packard Company (NYSE: HPQ) - For an in-depth report on Hewlett-Packard Company follow: www.BullTrends.com/stockquote/HPQ
Most active Nasdaq-traded stocks
AP - Tue Mar 25, 12:35PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Publication Reports Clinical Utility of BGM Galectin-3(R) Test for Prediction of Near-Term Rehospitalization in Patients With Heart Failure
GlobeNewswire - Tue Mar 25, 7:31AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results, in the American Heart Journal, of an analysis of aggregated data from three large, multicenter clinical research trials in the United States and Europe. The trials included a total of 902 heart failure patients and demonstrated that elevations of galectin-3 levels in blood, as measured using the BGM Galectin-3(R) Test, were significantly predictive of rehospitalization for heart failure as early as within the first 30 days following discharge from an initial hospital stay. [1]
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Insider Buying Is On The Rise In These 4 Rallying Stocks
at The Street - Thu Mar 20, 5:16PM CDT
James Dennin, Kapitall: One way to evaluate small cap stocks is by looking for insider buying, when people on staff are buying [...]
Why BG Medicine (BGMD) Hit a One-Year High Today (Update)
at The Street - Thu Mar 20, 3:41PM CDT
BG Medicine (BGMD) rose to a one-year high of $2.36 on Thursday after the diagnostics company reported fourth-quarter results that beat analysts' expectations. BG Medicine reported a loss of 6 cents a share, which beat the Capital IQ consensus...
BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy
GlobeNewswire - Thu Mar 20, 7:14AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) today announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled "Galectin-3 and Cardiac Resynchronization Therapy," to the Company. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood.
BG Medicine Reports 2013 Fourth Quarter and Year End Financial Results
GlobeNewswire - Thu Mar 20, 6:50AM CDT
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, today reported financial results for the three months ended and year ended December 31, 2013.
The Next Big Biotech Mover: Ariad Pharma
at The Street - Wed Mar 19, 1:00PM CDT
Ariad Pharmaceuticals could be the next biotech stock setting up for a monster move higher, according to Roberto Pedone.
Coverage of Top Gainers -- Research on Synta Pharma, BG Medicine, Abraxas Petroleum, and xG Technology
PR Newswire - Wed Mar 19, 7:25AM CDT
The US markets saw a positive sentiment on Tuesday, March 18, 2014, with the NASDAQ Composite closing at 4,333.31, up 1.25%, the Dow Jones Industrial Average ending the session at 16,336.19, up 0.55% and the S&P 500 edging 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Synta Pharmaceuticals Corp. (NASDAQ: SNTA), BG Medicine Inc. (NASDAQ: BGMD), Abraxas Petroleum Corp. (NASDAQ: AXAS), and xG Technology Inc. (NASDAQ: XGTI). Free technical research on SNTA, BGMD, AXAS and XGTI can be downloaded upon signing up at:
BG Medicine Announces Fiscal Year 2013 Financial Results Release Date and Conference Call Information
GlobeNewswire - Thu Mar 13, 3:48PM CDT
BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, March 20, 2014 at 8:30 a.m. Eastern Time to discuss its fiscal year 2013 financial results before the market opens.
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease
GlobeNewswire - Wed Mar 12, 7:46AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) welcomed today an announcement by La Jolla Pharmaceutical Company (LJPC) on March 10, 2014 of positive top-line results of its randomized, placebo-controlled Phase 2 trial of the galectin-3 inhibitor compound GCS-100 in chronic kidney disease. The trial met its primary efficacy endpoint of improvement in kidney function, as well as key secondary endpoints including a statistically significant reduction in circulating levels of galectin-3, the molecular target of GCS-100, at the effective therapeutic dose, as measured using the BGM Galectin-3 Test.
BG Medicine Compliant With NASDAQ Listing Requirements
GlobeNewswire - Tue Mar 11, 5:02PM CDT
BG Medicine, Inc. (Nasdaq:BGMD) (the "Company"